Representative Matters

Patent Litigation

  • Noble Systems Corp. v. Acqueon Technologies, Inc. et al. (Northern District of Texas, Dallas Division)
    • Represented multiple defendants in multi-patent infringement action involving call and contact center technologies and telephone systems.

  • Gensetix, Inc. et al. v. Baylor College Of Medicine et. al. (Southern District of Texas)
    • Represented Gensetix in patent infringement lawsuit.

  • Cephalon, Inc. v. Nang Kuang Pharmaceutical Co., Ltd. and CANDA NK-1, LLC (Eastern District of New York)
    • Represented Nang Kuang Pharmaceutical and CANDA NK-1 in Hatch-Waxman litigation related to chronic lymphocytic leukemia and non-Hodgkin's lymphoma drug Treanda®.

  • Laboratoire HRA Pharma v. Teva Pharmaceuticals USA, Inc. (District of Delaware)
    • Represented HRA in Hatch-Waxman litigation related to an emergency contraceptive drug ella®.

  • Andrulis Pharmaceuticals Corp. v. Celgene Corp. (District of Delaware)
    • Represented Andrulis in patent litigation related to the use of thalidomide in combination with an alkylating agent to treat certain cancers. 

  • Merck Sharp & Dohme Corp. v. Sandoz Inc. et al. ( District of New Jersey)
    • Represented Merck in Hatch-Waxman litigation related to an anti-nausea drug Emend IV®.

  • Helsinn Healthcare SA et al. v. Dr. Reddy’s Laboratories Ltd. et al. (District of New Jersey)
    • Represented Helsinn in Hatch-Waxman litigation related to an anti-nausea drug Aloxi®.

  • Gevo Inc. v. Betamax Advanced Biofuels LLC et al. (District of Delaware)
    • Represented Gevo in biotechnology litigation related to recombinant isobutanol Biofuel.

  • Medicis Pharmaceutical Corp. v. Actavis Mid Atlantic Inc. (District of Delaware)
    • Represented Medicis in Hatch-Waxman litigation related to Zyclara®, used for acne treatment.
  • Eisai and Novartis v. Lupin et al. (District of Delaware)
    • Represented Eisai in Hatch-Waxman litigation related to an anti-seizure drug Banzel®.

  • Daiichi Sankyo Inc. et al. v. Impax Laboratories Inc. et al. (District of Delaware)
    • Represented Daiichi Sankyo in Hatch-Waxman litigation related to Welchol®, used for the treatment of type-2 diabetes and high cholesterol.

  • Takeda Pharmaceutical Co. Ltd. and Takeda Pharmaceuticals North America Inc. v. Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc. (District of Delaware)
    • Represented Takeda in Hatch-Waxman litigation related to an anti-insomnia drug Rozerem®.

  • Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Ltd. v. Amgen Inc. (Eastern District of Pennsylvania)
    • Represented Amgen in patent infringement lawsuit related to Sensipar®, used for the treatment of secondary hyperparathyroidism.

  • Eli Lilly & Co. v. Teva Pharmaceuticals. Inc. (Southern District of Indiana)
    • Represented Eli Lilly in patent infringement lawsuit related to an osteoporosis drug Evista®.

 

Inter Partes Review

  • Neptune Generics LLC et. al. v. Eli Lilly (IPR2016-00237; IPR2016-00240)

    • Represented Neptune Generics in an inter partes review of U.S. Patent No. 7,772,209 related to a lung cancer drug Alimta®.

  • Coalition for Affordable Drugs VI, LLC (CFAD) v. Celgene Corporation (IPR2015-01092; IPR2015-01096; IPR2015-01102; IPR2015-01103)

    • Represented CFAD in an inter partes review of U.S. Patent Nos. 6,045,501 and 6,315,720 related to cancer drugs Thalomid®, Revlimid®, and Pomalyst®.

  • Coalition for Affordable Drugs (ADROCA), LLC v. Acorda Therapeutics, Inc. (IPR2015-00720; IPR2015-00817; IPR2015-01850; IPR2015-01853; IPR2015-01857; IPR2015-01858)

    • Represented ADROCA in an inter partes review of U.S. Patent Nos. 8,440,703, 8,007,826, 8,663,865, and 8,354,437 related to a multiple sclerosis drug Ampyra®.

  • nXn Partners, LLC v. Nissan Chemical Industries, Ltd. (IPR2016-00694)

    • Represented nXn Partners in an inter partes review of U.S. Patent No. 8,796,464 related to a flea treatment drug Bravecto®.

  • Coalition for Affordable Drugs II (CFAD) LLC v. Cosmo Tech. Ltd. (IPR2015-00988)

    • Represented CFAD in an inter partes review of U.S. Patent No. 6,773,720 related to a colitis drug Lialda®.

  • Rosellini Scientific, LLC v. Grunenthal GmbH (IPR2016-00471)

    • Represented Rosellini Scientific in an inter partes review of U.S. Patent No. 7,994,364 related to a pain drug Nucynta®.

  

© 2020 by KOTA LAW PLLC.  All rights reserved.  Disclaimer | Privacy Policy

  • Facebook Social Icon
  • LinkedIn Social Icon